Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Albuminuria Clear all
Terminated Phase 1 Interventional Results available

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877
View directory record Official record
Conditions
Type 2 Diabetic Nephropathy
Interventions
PF-03882845, Spironolactone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Chula Vista, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Not applicable Interventional

Early Identification and Action in CKD

NCT02208674
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Protocolized, pharmacist-delivered CKD Action Plan
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

NCT01989754
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Albuminuria
Interventions
Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
5,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands

NCT04626271
View directory record Official record
Conditions
Albuminuria
Interventions
ACR | U.S. Urine Analysis Test System, URiSCAN Optima Urine Analyzer
Device
Lead sponsor
Healthy.io Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Garden City, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

NCT00421733
View directory record Official record
Conditions
Diabetic Nephropathy, Chronic Kidney Disease
Interventions
Zemplar (paricalcitol) capsules, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
27
States / cities
Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Effect of Sulodexide in Early Diabetic Nephropathy

NCT00130208
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sulodexide, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jul 22, 2026, 5:55 AM EDT
Recruiting Phase 4 Interventional

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

NCT05498116
View directory record Official record
Conditions
Albuminuria
Interventions
Montelukast, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Not applicable Interventional Results available

Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23

NCT02020785
View directory record Official record
Conditions
Albuminuria
Interventions
Higher phosphorus period, Lower phosphorus period
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease

NCT00552409
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
Interventions
Cholecalciferol, Placebo
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Jul 22, 2026, 5:55 AM EDT
Terminated Phase 2 Interventional Results available

Rhubarb and Angiotensin Converting Enzyme Inhibitor

NCT00672451
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
rhubarb extract, placebo
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Not applicable Interventional

Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria

NCT00493727
View directory record Official record
Conditions
Diabetes, Proteinuria
Interventions
N-acetylcysteine(Mucomyst)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2008 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 3 Interventional

Sodium Lowering and Urinary Protein Reduction Trial

NCT02945969
View directory record Official record
Conditions
Chronic Kidney Disease, Albuminuria
Interventions
Low Sodium Diet
Behavioral
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
21 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jul 22, 2026, 5:55 AM EDT
Terminated Phase 4 Interventional Results available

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

NCT03029351
View directory record Official record
Conditions
Type2 Diabetes, Kidney Diseases
Interventions
Exenatide Extended Release for Inj Susp 2 MG, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 22, 2026, 5:55 AM EDT
Completed No phase listed Observational

Evaluation of Albuminuria HIV-Infected Patients

NCT00524992
View directory record Official record
Conditions
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

NCT01464320
View directory record Official record
Conditions
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
Interventions
ABT-614, Placebo Comparator
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Jul 22, 2026, 5:55 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

NCT00342927
View directory record Official record
Conditions
Diabetic Nephropathy, Diabetes Mellitus, Diabetic Kidney Disease, Albuminuria
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 99 Years
Enrollment
9,084 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Not applicable Interventional

Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD

NCT01459770
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
Medication Information Transfer Intervention, Usual care for hospital discharge
Other
Lead sponsor
Providence Medical Research Center
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria

NCT00625820
View directory record Official record
Conditions
Kidney Disease, Albuminuria
Interventions
6R BH4, Vitamin C
Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Jul 22, 2026, 5:55 AM EDT
Not listed Not applicable Interventional

Minocycline and Proteinuria in Diabetic Nephropathy

NCT01779089
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Minocycline 100 mg po bid for 6 months, placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

NCT06150924
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
44
States / cities
Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Terminated Phase 3 Interventional Results available

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)

NCT00549757
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
8,606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
118
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

NCT06350123
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Sheffield, Alabama • Glendale, California • Waterbury, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Not listed No phase listed Observational

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

NCT05214105
View directory record Official record
Conditions
Sickle Cell Disease, Kidney Diseases, Chronic
Interventions
Biospecimen/DNA collection and analysis
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Winston-Salem, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

NCT03118739
View directory record Official record
Conditions
Hyperuricemia, Albuminuria, Type 2 Diabetes
Interventions
Verinurad 9 mg+Febuxostat 80 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Canyon Country, California • Chula Vista, California • Corona, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Jul 22, 2026, 5:55 AM EDT